Standards of care in mesothelioma treatment

British Journal of Cancer, Published online: 22 September 2020; doi:10.1038/s41416-020-01078-yStandards of care in mesothelioma treatment
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsPlatinum ‐based chemotherapy followed by lung‐sparing surgery (P/D) and IMRT is a feasible and safe treatment modality that yields acceptable locoregional control in patients with locally advanced MPM; however, these results should be corroborated in larger studies.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
The U.S. House of Representatives last week failed to advance once-promising legislation that effectively would have banned asbestos, frustrating advocates once again. H.R. 1603, titled the Alan Reinstein Ban Asbestos Now Act of 2020, had been expected to pass easily under a Congressional procedure reserved for broadly supported, non-controversial legislation. The bipartisan House Committee on Energy and Commerce had voted earlier, 47-1, to move it forward, fueling considerable optimism leading into the latest Congressional session. If passed, the bill would have then moved to the U.S. Senate, which also had shown bipartis...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract Malignant pleural mesothelioma is an aggressive, deadly cancer often requiring input from multiple medical disciplines. Treatment has evolved over the last several decades with increasing evidence and ongoing advances in chemotherapy, radiation, and immunotherapy; however, no standard treatment regimen has yet been defined. Regardless of the overall strategy, surgery remains the foundation of treatment to remove macroscopic disease, and preservation of lung parenchyma via extended pleurectomy/decortication may be preferable to extrapleural pneumonectomy. PMID: 33012435 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
Abstract Extrapleural pneumonectomy (EPP) is the most extensive form of surgery for mesothelioma, involving en bloc resection of visceral and parietal pleura, lung, diaphragm and pericardium, with reconstruction of the pericardium and diaphragm. It can be performed safely in carefully selected patients. It should be performed in experienced centers as part of a multimodality treatment plan. The SMART approach, with a short course of induction hemithoracic radiation followed by EPP has demonstrated safety and value of hypofractionated hemithoracic radiation combined with complete macroscopic resection. We are condu...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
Abstract Staging of malignant pleural mesothelioma has been challenging because of a paucity of cases and poor survival. At least 5 staging systems were proposed before 1990 until the first consensus system was published in 1995. This system used tumor, node, metastasis designations and borrowed heavily from parenchymal lung cancer descriptors. With the establishment of a database to collect cases from 1995 to 2013, evidence-based revisions to the 1995 staging classification were published in 2016. With improving imaging technology, clinical staging will become more refined and, it is hoped, more useful for progno...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
Pharmaceutical giant Johnson &Johnson has agreed to pay more than $100 million to settle an more than a thousand lawsuits claiming its iconic baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson &Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a cornstarch-base...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Pharmaceutical giant Johnson &Johnson has agreed to pay more than $100 million to settle more than a thousand lawsuits claiming its iconic talc-based baby powder caused cancer, according to Bloomberg News. The settlement stems from burgeoning litigation after earlier asbestos-contaminated talc was found in one of its products. Johnson &Johnson, the world’s largest maker of health care merchandise, recalled 33,000 bottles of its baby powder in 2019, “out of an abundance of caution.” It also stopped selling talc-based baby powder the same year in the United States and Canada, switching to a cornsta...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Title: Drug Combo Approved for First-Line Treatment of MesotheliomaCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM
Source: MedicineNet Cancer General - Category: Cancer & Oncology Source Type: news
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Mesothelioma | UK Health